Fauvet Girel Stocks - FAUV.PA rate on the chart online today: price forecast, profitability, dividends – Oninvest

Review

Evaluation

Target price

Dynamics

Performance

Growth

Dividends

Risks

€ 0

Key Takeaways

Risk factor

Considerable default risk

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only

Data is available to registered users only

Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts

Sign up to access all the key risk and return factors

Risks

Default risk
Data is available to registered users only
Volatility
Data is available to registered users only
Selling difficulty
Data is available to registered users only
Stress test
Data is available to registered users only
Country risks
Data is available to registered users only
Other risks
Data is available to registered users only

Sign up to access detailed risk analysis

About

As per the transaction announced on October 15, 2021, operates as a subsidiary of Advanced Biological Laboratories (ABL) S.A.

Greatly overvalued

1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only

Sign up to access detailed valuation

Risks

Default risk
Data is available to registered users only
Volatility
Data is available to registered users only
Selling difficulty
Data is available to registered users only
Stress test
Data is available to registered users only
Country risks
Data is available to registered users only
Other risks
Data is available to registered users only

Sign up to access detailed risk analysis